RARS1 and lung carcinoma: Indeed, in thinking about the next step in our studies, the finding that certain lung cancers express specific, known therapeutic NR targets (e.g., PR, ERα, ERβ, AR, RARs, and PPARs) brings up the possibility of treating patients whose tumors express these receptors with drugs (agonists or antagonists) that target the receptors.